These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 7896179)
21. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127 [TBL] [Abstract][Full Text] [Related]
22. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer. Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887 [TBL] [Abstract][Full Text] [Related]
23. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Covens A; Blessing J; Bender D; Mannel R; Morgan M; Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022 [TBL] [Abstract][Full Text] [Related]
24. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH; Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801 [TBL] [Abstract][Full Text] [Related]
25. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125 [TBL] [Abstract][Full Text] [Related]
26. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
27. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790 [TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440 [TBL] [Abstract][Full Text] [Related]
29. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408 [TBL] [Abstract][Full Text] [Related]
30. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
32. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709 [TBL] [Abstract][Full Text] [Related]
35. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544 [TBL] [Abstract][Full Text] [Related]
36. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689 [TBL] [Abstract][Full Text] [Related]
37. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin. Markman M; Cleary S; Lucas W; Weiss R; Howell SB Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962 [TBL] [Abstract][Full Text] [Related]
38. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Hussain M; Salwen W; Kucuk O; Ensley J Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-43-S19-45. PubMed ID: 9427265 [TBL] [Abstract][Full Text] [Related]